After Paris attacks, Isis Pharma finally mulls a name change

The rise of al-Qaeda offshoot ISIS has led to at least one similarly named company, the former Isis Wallet, to rebrand itself. But Isis Pharmaceuticals ($ISIS), which has been in business for 25 years and owns the eponymous ticker, has to this point refused to back away from its moniker. Now, days after the other ISIS carried out attacks in Paris that left more than 100 people dead, the biotech is considering a name change.

"Even though people know we're not associated with the terrorist group, the name itself has so many negative connotations," Isis Vice President D. Wade Walke told CNN Money, adding that the company hasn't made a final decision on whether to abandon its long-held name.

The Isis-ISIS issue first came up last year, when founder and CEO Stanley Crooke faced repeated questions about what it was like to do business under a suddenly infamous name. But Crooke and company remained obstinate, insisting that their customers and shareholders would never confuse a drug developer for a global terrorist outfit.

Isis CEO Stan Crooke

"It drives me crazy," Crooke told CNBC's Jim Cramer in September 2014. "But we're not a retail company. Our investors should be sophisticated, and we've been Isis for 25 years, and I don't feel like I want to capitulate to these terrorists by changing my name. They can change their name."

And they have. Last year, the group shortened its name to simply Islamic State, or IS. Further complicating matters, the U.S. Department of State, which formerly called the group ISIL, has more recently referred to it as Daesh, echoing its allies in the region.

But still it is "ISIS" that remains on headlines and chyrons around the world, and on the minds at Crooke's company. The terrorist group's rising profile hasn't adversely affected business in any way, Walke told CNN, but "subliminally, it can't help."

- read the story

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.